Metabolic Syndrome – Underlying Mechanisms and Drug Therapies

Minghan Wang is the Scientific Director and member of the Senior Leadership Team for Metabolic Disorders Research at Amgen. He has authored 30 peer-reviewed publications and holds 2 patents.

Introduction ( Minghan Wang ). Contributors. Part I. The physiology of metabolic tissues under normal and disease states. Chapter 1: Gut as an endocrine organ: the role of nutrient-sensing in energy metabolism ( Minghan Wang ). Chapter 2: Central glucose sensing and control of food intake and energy homeostasis ( Lourdes Mounien and Bernard Thorens ). Chapter 3: Abnormalities in insulin secretion in type 2 diabetes mellitus ( Taly Meas and Pierre-Jean Guillausseau ). Chapter 4: Adipokine production by adipose tissue: A novel target for treating metabolic syndrome and its sequelae ( Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and Peter Zahradka ). Chapter 5: Hepatic metabolic dysfunctions in type 2 diabetes: Insulin resistance and impaired glucose production and lipid synthesis ( Ruojing Yang ). Chapter 6: Energy metabolism in skeletal muscle and its link to insulin resistance ( Minghan Wang ). Part II. Metabolic diseases and current therapies. Chapter 7: Mechanisms and complications of metabolic syndrome ( Minghan Wang ). Chapter 8: Emerging therapeutic approaches for dyslipidemia associated with high LDL and low HDL ( Margrit Schwarz and Jae B. Kim ). Chapter 9: Mechanism of action of niacin: implications for atherosclerosis and drug discovery ( Devan Marar, Shobha H. Ganji, Vaijinath S. Kamanna, and Moti L. Kashyap ). Chapter 10: Current anti-diabetic therapies and mechanisms ( Minghan Wang ). Part III. Drug targets for anti-diabetic therapies. Chapter 11: GLP-1 biology, signaling mechanisms, physiology, and clinical studies ( Remy Burcelin, Cendrine Cabou1, Christophe Magnan, and Pierre Gourdy ). Chapter 12: Dipeptidyl peptidase IV inhibitors for treatment of diabetes ( McIntosh, CHS, Kim, S-J., Pederson, RA, Heiser, U, and Demuth, H-U ). Chapter 13: Sodium glucose co-transporter 2 inhibitors ( Margaret Ryan and Serge A. Jabbour ). Chapter 14: Fibroblast growth factor 21 as a novel metabolic regulator ( Radmila Micanovic, James D. Dunbar, and Alexei Kharitonenkov ). Chapter 15: Sirtuins as potential drug targets for metabolic diseases ( Qiang Tong ). Chapter 16: 11?-hydroxysteroid dehydrogenase type 1 as a therapeutic target for type 2 diabetes ( Clarence Hale and David J. St. Jean, Jr. ). Chapter 17: Monoclonal antibodies for the treatment of type 2 diabetes: A case study with glucagon receptor blockade ( Hai Yan, Wei Gu, and Murielle Veniant-Ellison ). Part IV. Lessons learned and future outlook. Chapter 18: Drug development for metabolic diseases: past, present and future ( Minghan Wang ). Index.